Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Adia Med Q3 2026 Results: Net Loss of $53K

Adia Med, Inc. reported total revenue of $1,019,245 for the nine months ended September 30, 2026, a significant increase from $521,958 in the prior year, driven primarily by medical procedures and biologics sales. Despite the revenue growth, the company realized a net loss of $271,922 for the period as operating expenses, particularly legal and professional fees and salaries, increased substantially.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.50.3
Gross profit0.20.2
Profit before tax-0.10.1
Net income-0.10.1
EPS (diluted, $ a share)$-0.00$0.00

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+36.8%
Gross margin48.6%
Operating margin-8.6%
Source

10-Q filed with the SEC, OTC: ADIA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Adia Med, Inc.: key numbers

Share price
$0.1280Close, Nov 13
Market cap
$12.1M
Shares outstanding
94.4MLatest SEC cover page
Sector
Life Sciences
Industry
Medicinal Chemicals & Botanical ProductsSIC 2833

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Adia Med, Inc.

All →
11:23 AM ET 8-K
Divestiture

Adia Med Divestiture to Larry A. Powalisz

Adia Med, Inc. entered into a Membership Interest Purchase Agreement to sell a 7% membership interest in its subsidiary, Adia Labs LLC, to the company's CEO, Larry A. Powalisz. The transaction is valued at $350,000 in cash, with the use of proceeds restricted to corporate purposes jointly approved by the company's independent directors.

Counterparty
Larry A. Powalisz
7:46 AM ET 8-K
Loan & Debt

Adia Med $935K Debt Financing with Larry Powalisz

Adia Med, Inc. fully repaid and discharged its $1.0 million unsecured revolving line of credit facility with its CEO, Larry Powalisz. The company made two payments totaling $934,970.94, which included $74,658.94 in accrued interest, to satisfy the debt in full. This related-party facility, originally entered into in June 2024, is now terminated following the final payment on October 9, 2026.

Value
$935K
Counterparty
Larry Powalisz
6:01 AM ET 8-K
Divestiture

Adia Med Divestiture to Live Oak Health LLC for $1.5M

Adia Med, Inc. entered into a Membership Interest Purchase Agreement to sell a 30% interest in its subsidiary, Adia Labs LLC, to Live Oak Health LLC (dba QCM Biologics) for $1.5 million. The consideration consists of $1.0 million in cash and a $0.5 million promissory note, with the buyer also receiving an option to purchase an additional 10% stake for $0.5 million. Despite the minority equity sale, the agreement establishes equal 50/50 voting power between Adia Med and the buyer regarding member matters.

Value
$1.5M
Counterparty
Live Oak Health LLC
4:49 PM ET 8-K
Court & Legal Update

Adia Med Court & Legal Update

Adia Med, Inc. filed a declaratory judgment lawsuit in Florida against Tydus Richards and other purported shareholders to quiet title in 29,059,792 shares of common stock. The company alleges the shares, representing approximately 30.78% of its outstanding stock, were never validly issued or paid for. If successful, the action would allow the company to cancel and retire these shares, significantly reducing its total share count.

Counterparty
Tydus Richards

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.